Biolegend, 135214, FITC anti-mouse CD279 (PD-1) Antibody, 200μg

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
200μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
Application References(PubMed link indicates BioLegend citation): Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed Li X, et al. 2023. J Clin Invest. 133:. PubMed Nguyen T, et al. 2023. Nat Commun. 14:3357. PubMed Liu H, et al. 2022. Cancer Immunol Res. 10:1028. PubMed Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Wang L, et al. 2019. Cell Rep. 29:1848. PubMed Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed Gengenbacher M, et al. 2016. MBio. 7: 00679-16. PubMed Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed Weigelin B, et al. 2015. Proc Natl Acad Sci U S A. 112:7551. PubMed Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed Xu X, et al. 2020. J Cell Biol. 219:00:00. PubMed Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed Mathur S, et al. 2021. JCI Insight. 6:. PubMed Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed Li J, et al. 2020. Cancer Discov. . PubMed Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed Rios D, et al. 2015. Mucosal Immunol. 101038/mi. PubMed Mintz MA, et al. 2019. Immunity. 51:310. PubMed Li J, et al. 2018. Immunity. 49:178. PubMed Poillet-Perez L, et al. 2020. Nat Cancer. 1:923. PubMed Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed Zeis P, et al. 2020. Immunity. 53:775. PubMed He X, et al. 2021. J Immunother Cancer. 9:. PubMed Hartmann W, et al. 2020. Cell Reports. 29(8):2243-2256.e4.. PubMed Truckenbrod EN, et al. 2021. Elife. 10:. PubMed Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed Pai CS, et al. 2020. Immunity. 50(2):477-492. PubMed Lavoie S, et al. 2020. Gastroenterology. 158:1359. PubMed Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed Li H, et al. 2022. iScience. 25:104481. PubMed Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed Chen S, et al. 2018. Nat Commun. 9:5298. PubMed Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
RRID: AB_10689633 (BioLegend Cat. No. 135213) AB_10680238 (BioLegend Cat. No. 135214)
Structure: A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution: Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
Function: Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor: B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, T cells
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313
Gene ID: 18566
UniProt: View information about CD279 on UniProt.org
Clone: 29F.1A12
Regulatory Status: RUO
Other Names: PD-1, Programmed Death-1, PDCD1
Isotype: Rat IgG2a, κ